title: Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ciccone
authors.forename: C
authors.initials: C
authors.lastname: Motto
authors.forename: E
authors.initials: E
authors.lastname: Aritzu
authors.forename: A
authors.initials: A
authors.lastname: Piana
authors.forename: L
authors.initials: L
authors.lastname: Candelise
mesh_terms: D000208:Acute Disease; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000401:mortality; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000009:adverse effects*
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013300:Streptokinase; D001241:Aspirin